Experimental HCV Drugs
Experimental HCV Drugs
EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
- Details
- Category: HCV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by Liz Highleyman
A dual oral regimen containing the hepatitis C polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological rates overall, but this was driven by very good response among people with HCV genotype 2, while those with genotype 3 did not fare as well, researchers reported this week at the 48th EASL International Liver Congress (EASL 2013) in Amsterdam.
EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1
- Details
- Category: HCV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by Keith Alcorn
A 4-drug combination of direct-acting antivirals developed by AbbVie cured genotype 1 hepatitis C virus (HCV) infection in over 90% of participants in the AVIATOR study, without the need for the use of interferon, researchers reported at the 48th International Liver Congress (EASL 2013) on Thursday in Amsterdam. A 12-week treatment course will go forward to Phase 3 studies.
Janssen Submits Approval Requests for New Hepatitis C Drug Simeprevir
- Details
- Category: HCV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Janssen
Janssen has submitted requests for approval in the U.S. and Europe for its investigational HCV protease inhibitor simeprevir (formerly TMC435) as an addition to interferon-based therapy for people with genotype 1 or 4 chronic hepatitis C virus infection. The company announced that it filed a New Drug Application with the U.S. Food and Drug Administration (FDA) on March 28, followed by a Marketing Authorisation Application to the European Medicines Agency (EMA) on April 24.
EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
- Details
- Category: HBV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Liz Highleyman
The EASL International Liver Congress is now underway at the Amsterdam RAI congress center. At a Wednesday press conference, EASL officials gave a preview of some of the hepatitis C treatment highlights -- both augmentation of interferon-based therapy and interferon-free regimens -- to be presented at the meeting, which runs through Sunday.
Daclatasvir + Asunaprevir Works Well for Patients Who Cannot Use Interferon
- Details
- Category: HCV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Liz Highleyman
A dual combination of the HCV NS5A inhibitor daclatasvir (formerly BMS-790052) and HCV protease inhibitor asunaprevir (formerly BMS-650032) cured three-quarters of Japanese patients unable to take interferon, including 90% of prior null responders, according to a study described in the April 2013 Journal of Hepatology.
Web Design and Development by